CSF levels of HoxB3 and YKL-40 may predict conversion from clinically isolated syndrome to relapsing remitting multiple sclerosis

Basit Öğe Kaydı
dc.contributor.authorTamam, Yusuf
dc.contributor.authorGunes, Betul
dc.contributor.authorAkbayir, Ece
dc.contributor.authorKizilay, Tugce
dc.contributor.authorKaraaslan, Zerrin
dc.contributor.authorKoral, Gizem
dc.contributor.authorDuzel, Berna
dc.date.accessioned2024-04-24T16:15:39Z
dc.date.available2024-04-24T16:15:39Z
dc.date.issued2021
dc.departmentDicle Üniversitesien_US
dc.description.abstractIntroduction: Multiple sclerosis (MS) often initiates with an acute episode of neurological disturbance, known as clinically isolated syndrome (CIS). There is an unmet need for biomarkers that differentiate patients who will convert to MS and who will remain as CIS after the first attack. Methods: First attack serum and cerebrospinal fluid (CSF) samples of 33 CIS patients were collected and these patients were divided as those who converted to MS (CIS-MS, n=17) and those who continued as CIS (CIS-CIS, n=16) in a 3-year follow-up period. Levels of homeobox protein Hox-B3 (HoxB3) and YKL-40 were measured by ELISA in samples of CIS-CIS, CIS-MS, relapsing remitting MS (RRMS) patients (n=15) and healthy controls (n=20). Results: CIS-CIS patients showed significantly reduced CSF levels of YKL-40 and increased serum/CSF levels of HoxB3 compared with CIS-MS and RRMS patients. CIS-MS and RRMS patients had comparable YKL-40 and HoxB3 level profiles. Receiver operating characteristic (ROC) curve analysis showed the highest sensitivity for CSF HoxB3 measurements in prediction of CIS-MS conversion. Kaplan-Meier analysis demonstrated that CIS patients with lower CSF HoxB3 (<3.678 ng/ml) and higher CSF YKL-40 (>654.9 ng/ml) displayed a significantly shorter time to clinically definite MS. Conclusion: CSF levels of HoxB3 and YKL-40 appear to predict CIS to MS conversion, especially when applied in combination. HoxB3, which is a transcription factor involved in immune cell activity, stands out as a potential candidate molecule with biomarker capacity for MS.en_US
dc.description.sponsorshipDicle University [TIP.20.003]en_US
dc.description.sponsorshipY. Tamam, B. Gunes, E. Akbayir, T. Kizilay, Z. Karaaslan, G. Koral, B. Duzel, CI. Kucukali, T. Gunduz, M. Kurtuncu, V. Yilmaz, E. Tuzun, and R. Turkoglu report no disclosures. This study is supported by Dicle University scientific research projects unit (TIP.20.003) .en_US
dc.identifier.doi10.1016/j.msard.2020.102697
dc.identifier.issn2211-0348
dc.identifier.issn2211-0356
dc.identifier.pmid33352356
dc.identifier.scopus2-s2.0-85098112218
dc.identifier.scopusqualityQ2
dc.identifier.urihttps://doi.org/10.1016/j.msard.2020.102697
dc.identifier.urihttps://hdl.handle.net/11468/15883
dc.identifier.volume48en_US
dc.identifier.wosWOS:000657748800001
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherElsevier Sci Ltden_US
dc.relation.ispartofMultiple Sclerosis and Related Disorders
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectMultiple Sclerosisen_US
dc.subjectClinically Isolated Syndromeen_US
dc.subjectHoxb3en_US
dc.subjectYkl-40en_US
dc.subjectBiomarkeren_US
dc.titleCSF levels of HoxB3 and YKL-40 may predict conversion from clinically isolated syndrome to relapsing remitting multiple sclerosisen_US
dc.titleCSF levels of HoxB3 and YKL-40 may predict conversion from clinically isolated syndrome to relapsing remitting multiple sclerosis
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu